Kadcyla
Kadcyla ingredients
| Active ingredient | Strength |
|---|---|
| Trastuzumab Emtansine | 20 mg/mL |
What Kadcyla is used for
The FDA lists the approved uses on the official label (below). In the EU, trastuzumab emtansine is approved as Kadcyla for:
Early Breast Cancer (EBC) Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy. Metastatic Breast Cancer (MBC) Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: Received prior therapy for locally advanced or metastatic disease, or Developed disease recurrence during or within six months of completing adjuvant therapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Kadcyla
- Generic name
- Ado-trastuzumab emtansine
- Made by
- Genentech, Inc.
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- FDA approval
- Biologic licence (BLA) BLA125427
- On the US market since
- 2013
Official information
- Kadcyla prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Ado-trastuzumab emtansine)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kadcyla?
Kadcyla (Ado-trastuzumab emtansine) is a cancer medicine made by Genentech, Inc., approved by the US FDA.
What are the ingredients of Kadcyla?
Kadcyla contains Trastuzumab Emtansine (20 mg/mL).
Is Kadcyla approved in Europe?
The same active substance is approved in the EU as Kadcyla.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA